SIMPSON, CURRAN MATTHEW,YOO, STEPHEN,KOZARSKY, KAREN FRAN,REINHARDT, RICKEY ROBERT,CORUZZI, LAURA A.
申请号：
CA3019665
公开号：
CA3019665A1
申请日:
2017.04.14
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Compositions and methods are described for the delivery of a fully human post- translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration ("nAMD"), also known as "wet" age-related macular degeneration ("WAMD"), age-related macular degeneration ("AMD"), and diabetic retinopathy.
